![Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use](https://newsology.co.in/wp-content/uploads/https://image.cnbcfm.com/api/v1/image/107243424-1684423444823-gettyimages-960428256-p1230194.jpeg?v=1712591695&w=1920&h=1080)
Pfizer’s RSV vaccine shows potential to protect high-risk adults ages 18-59, widening possible use
[ad_1] Respiratory syncytial virus – viral vaccine under research Hailshadow | Istock | Getty Images A vaccine from Pfizer showed the potential to protect adults ages 18 to 59 who are at increased risk of getting severely sick from respiratory syncytial virus in a late stage clinical trial, the company said Tuesday. The initial data…